Belluscura PLC
LSE:BELL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (38.9), the stock would be worth GBX16.47 (2 096% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.8 | GBX0.75 |
0%
|
| 3-Year Average | 38.9 | GBX16.47 |
+2 096%
|
| 5-Year Average | 80.9 | GBX34.22 |
+4 462%
|
| Industry Average | 0 | GBX0 |
-100%
|
| Country Average | 0 | GBX0 |
-100%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
GBX2.4m
|
/ |
Jul 2024
$1.8m
|
= |
|
|
GBX2.4m
|
/ |
Dec 2024
$4.4m
|
= |
|
|
GBX2.4m
|
/ |
Dec 2025
$12.8m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
B
|
Belluscura PLC
LSE:BELL
|
3m GBP | 1.8 | -0.2 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 15.9 | 58.1 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 3.6 | 26 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 5.4 | 38.2 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 3.5 | 23 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 4.7 | 24.6 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 7 | 43.3 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 2 | 18.9 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 10.6 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 2.7 | 24.1 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 5.8 | 21.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 3 279.7 |
Other Multiples
Belluscura PLC
Glance View
Belluscura Plc engages in the provision of medical devices. The Company’s product, the X-PLO2R, is a lightweight portable oxygen concentrator (POC), which is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company focuses on devices and treatments involving oxygen. The X-PLO2R DX is designed to produce approximately six-liters pulse dose oxygen and approximately two-liters of flow oxygen. The firm is focused on developing the medical devices for treating people who are suffering from chronic lung diseases, such as the chronic obstructive pulmonary disease (COPD), respiratory distress caused by coronavirus disease (COVID-19), and other respiratory disorders.
